Home > Publications database > The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. > print

001     182408
005     20240229145718.0
024 7 _ |a 10.1007/s00392-022-02119-7
|2 doi
024 7 _ |a pmid:36289063
|2 pmid
024 7 _ |a 0300-5860
|2 ISSN
024 7 _ |a 1435-1285
|2 ISSN
024 7 _ |a 1861-0684
|2 ISSN
024 7 _ |a 1861-0692
|2 ISSN
024 7 _ |a altmetric:142096254
|2 altmetric
037 _ _ |a DKFZ-2022-02629
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kolwelter, Julie
|b 0
245 _ _ |a The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.
260 _ _ |a Berlin
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1675341870_2342
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 Jan;112(1):134-144
520 _ _ |a Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patients with CHF.In a double-blind, randomised (2:1), placebo-controlled, parallel-group, clinical trial, 74 patients with NYHA class II-III CHF and an ejection fraction of 49% or less received empagliflozin 10 mg once daily or placebo for 3 months. In each patient, tissue sodium content of the lower leg was assessed non-invasively by sodium-MRI (23Na-MRI) at baseline, after 1 and 3 months of treatment.After 1 and 3 months treatment with empagliflozin (n = 48), a significant decrease in skin sodium content was observed (1 month: 22.8 ± 6.1 vs. 21.6 ± 6.0 AU, p = 0.039; 3 months: 22.9 ± 6.1 vs. 21.6 ± 6.1 AU, p = 0.013), while there was no change in muscle sodium and muscle water content. In direct comparison, the change in skin sodium content between baseline and 3 months was - 1.3 ± 3.5 AU in the empagliflozin group versus 0.6 ± 3.5 AU in the placebo group (p for between-group difference = 0.022). No significant difference regarding change in muscle sodium and in muscle water content was observed after 3 months treatment between the two groups.This trial showed a significant decrease in skin sodium content after 1 and 3 months of treatment with empagliflozin. The decrease in skin sodium content may reflect a decrease in subclinical micro-oedema or/and in non-osmotic bound tissue sodium, both reported to impair left ventricular function.NCT03128528 ( http://www.gov ).25th April 2017.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Chronic heart failure
|2 Other
650 _ 7 |a Empagliflozin
|2 Other
650 _ 7 |a Magnetic resonance imaging
|2 Other
650 _ 7 |a SGLT2 inhibitor
|2 Other
650 _ 7 |a Sodium
|2 Other
650 _ 7 |a Tissue sodium content
|2 Other
700 1 _ |a Kannenkeril, Dennis
|b 1
700 1 _ |a Linz, Peter
|b 2
700 1 _ |a Jung, Susanne
|b 3
700 1 _ |a Nagel, Armin M
|0 P:(DE-He78)054fd7a5195b75b11fbdc5c360276011
|b 4
|u dkfz
700 1 _ |a Bosch, Agnes
|b 5
700 1 _ |a Ott, Christian
|b 6
700 1 _ |a Bramlage, Peter
|b 7
700 1 _ |a Nöh, Lisa
|b 8
700 1 _ |a Schiffer, Mario
|b 9
700 1 _ |a Uder, Michael
|b 10
700 1 _ |a Achenbach, Stephan
|b 11
700 1 _ |a Schmieder, Roland E
|b 12
773 _ _ |a 10.1007/s00392-022-02119-7
|0 PERI:(DE-600)2218331-0
|n 1
|p 134-144
|t Clinical research in cardiology
|v 112
|y 2023
|x 0300-5860
909 C O |p VDB
|o oai:inrepo02.dkfz.de:182408
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)054fd7a5195b75b11fbdc5c360276011
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN RES CARDIOL : 2022
|d 2023-08-26
920 1 _ |0 I:(DE-He78)E020-20160331
|k E020
|l E020 Med. Physik in der Radiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21